65,437 trials
Fallopian Tube Clear Cell Adenocarcinoma · Ovarian Clear Cell Adenocarcinoma · Recurrent Fallopian Tube Carcinoma
Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants
Breast Cancer
Primary: Disease Free Survival — 141; 135; 191; 560 Participants — p=0.0007
Renal Insufficiency, Chronic
Primary: Change in Total Body Water — -0.075; -4.36 litres — p=<0.001
Iron Deficiency Anemia · Iron Deficiency Anaemia
Primary: Number of Subjects With Adverse Drug Reactions (ADR) — 5 Participants
Healthy
Primary: Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination — 0; 0; 0; 0 Participants
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Primary: Cmax — 0.940; 2.00; 2.24; 2.11 ng/mL
Thyroid Eye Disease · Graves' Orbitopathy
Primary: Percentage of Participants Who Were Proptosis Responders at Week 24 — 9.5; 82.9 percentage of participants — p=<0.001
Lymphoma, Non-Hodgkin's
Primary: Overall Response Rate — 53.8 percentage of participants
Provoked Vestibulodynia
Primary: Change in Vulvslgesiometer Pain Rating From Baseline to One Month Post-treatment to 6 Months Post-treatment — 6.66; 6.62; 3.21; 3.60 score on a scale
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Poliomyelitis
Primary: Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity — 187; 179; 175; 149 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level. — -695.2; 216.7 U/L
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Cancer of the Cervix · Cervical Neoplasms
Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)